Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZD55 + interferon beta
- Development stage
- Preclinical
- Lead developer
- Shanghai Sunway Biotech
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
ZD55 + interferon beta is a combination therapy consisting of an oncolytic adenovirus (ZD55) engineered to express **human interferon beta (IFN-β)**. ZD55 is a modified type 5 adenovirus with E1B-55K gene deletion, making it selectively replicate in and lyse tumor cells. The expressed interferon beta exerts antitumor effects via induction of apoptosis and immune modulation. In preclinical studies and early development, ZD55-IFN-β demonstrated direct oncolytic activity as well as enhancement of anti-tumor immune responses. The therapy is primarily being studied for various malignancies, with demonstrated activity in models of cancer, either alone or in combination with agents such as doxorubicin[1].
- Other names
- ZD55-IFN-β
02
Targets
ATM (Ataxia telangiectasia mutated protein)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on ZD55 + interferon beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZD55 + interferon beta.